Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion has submitted an IND amendment application to the US FDA for the Phase 3 clinical trial of CT-P55 (a Cosentyx biosimilar candidate).
📊 [Key Disclosure Details & Financial Summary]
- Disclosure Title: Application for Amendment of Phase 3 Clinical Trial Plan for CT-P55 (Cosentyx Biosimilar) in the US
- Filing Date & Regulatory Agency: March 12, 2026 (Local time) / US Food and Drug Administration (FDA)
- Clinical Trial Phase: Global Phase 3
- Target Indication: Plaque psoriasis
- Clinical Trial Title: A randomized, active-controlled, double-blind, Phase 3 study to compare the efficacy and safety of CT-P55 and Cosentyx in patients with moderate to severe plaque psoriasis
- Trial Registration Number: EU CT number 2024-513348-27-00
- Trial Design & Duration:
- Number of Subjects: 153 patients
- Duration: 56 weeks
- Design: Randomized, active-controlled, double-blind, Phase 3 study
- Board Resolution / Fact Confirmation Date: March 12, 2026 (Filing date of the IND amendment with the US FDA)
- Investment Caution: Statistically, the final approval rate for clinical drug candidates is approximately 10%. Unforeseen results during trial or approval stages may lead to changes or cancellation of commercialization plans.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of US FDA Approval for Phase 3 IND Amendment
This disclosure details Celltrion’s IND amendment application for CT-P55 submitted to the US FDA, making it important to monitor regulatory approval decisions. Tracking the regulatory outcome is necessary to confirm subsequent clinical trial execution under the updated protocol. Regulatory decisions and trial progress updates can be verified through future regulatory disclosures or upcoming periodic filings (Quarterly, Half-Yearly, or Annual Business Reports).
📢 Disclaimer & Source Information
Source: This content was newly generated and structured based on official data submitted to the Data Analysis, Retrieval and Transfer System (DART) of the Financial Supervisory Service.
Investment Risk Notice: This information is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.
